Cost-Effectiveness of A Left Atrial Appendage Closure Device In Patients With Non-Valvular Atrial Fibrillation Unable or Unwilling to Tolerate Oral Anticoagulant Therapy In Italy And Spain

Approximately 18-20% of non-valvular atrial fibrillation (NVAF) patients are unable or unwilling to tolerate oral anticoagulant therapy (OAT), leaving them at risk of stroke. Left atrial appendage closure (LAAC) device offers an alternative stroke risk reduction strategy that enables the majority of patients to discontinue long-term systematic OAT. Acknowledging both potential improvements in health outcomes and additional upfront implantation costs of a LAAC device, this study considers the lifetime costs and benefits of LAAC compared to aspirin plus clopidogrel (A+C) in high-risk NVAF patients ineligible or unwilling to take OAT from the Italian and Spanish public healthcare payer perspectives.

Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: A Amin, I Cruz González, V Reddy, D Holmes, S Berti, A Iñiguez Romo, L De Deppo, V Priest, M Simmonds, C Lee, M Wasserman, A Margonato Source Type: research